{
    "root": "35a6e911-503e-ef0d-e063-6294a90a07e1",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Naltrexone Hydrochloride",
    "value": "20250521",
    "ingredients": [
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE (1600000 WAMW)",
            "code": "RFW2ET671P"
        },
        {
            "name": "ANHYDROUS LACTOSE",
            "code": "3SY5LH9PMK"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "NALTREXONE HYDROCHLORIDE",
            "code": "Z6375YW9SF"
        }
    ],
    "indications": "Naltrexone Hydrochloride Tablets USP are indicated in the treatment of alcohol dependence and for the blockade of the effects of exogenously administered opioids.\n                  Naltrexone Hydrochloride Tablets USP have not been shown to provide any therapeutic benefit except as part of an appropriate plan of management for the addictions.",
    "contraindications": "To reduce the risk of precipitated withdrawal in patients dependent on opioids, or exacerbation of a preexisting subclinical withdrawal syndrome, opioid-dependent patients, including those being treated for alcohol dependence, should be opioid-free (including tramadol) before starting naltrexone hydrochloride tablets treatment. An opioid-free interval of a minimum of 7 to 10 days is recommended for patients previously dependent on short-acting opioids.",
    "warningsAndPrecautions": "Naltrexone Hydrochloride Tablets, USP are available as:\n                  50 mg; yellow, round film-coated tablets, bisected on one side, debossed with \"EL\" on one side of the bisect and \"15\" on the other side of the bisect. They are available in\n                  \n                  NDC: 70518-4344-00\n                  PACKAGING: 30 in 1 BLISTER PACK\n                  \n                  Store at 20째 to 25째C (68째 to 77째F) [See USP Controlled Room Temperature].\n                  Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required). Protect from light.\n                  KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.\n                  \n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions": "Naltrexone hydrochloride is contraindicated in:\n                  \n                     Patients receiving opioid analgesics.\n                     Patients currently dependent on opioids, including those currently maintained on opiate agonists (e.g., methadone) or partial agonists (e.g., buprenorphine).\n                     Patients in acute opioid withdrawal (see\n  \n   \n                           WARNINGS\n                        ).\n \n  \n                     Any individual who has failed the naloxone challenge test or who has a positive urine screen for opioids.\n                     Any individual with a history of sensitivity to naltrexone hydrochloride or any other components of this product. It is not known if there is any cross-sensitivity with naloxone or the phenanthrene containing opioids."
}